Multiple sclerosis (MS) is a disease which affects the brain and spinal cord and causes muscle tremors and loss of balance over time. In some cases, it can cause permanent disorders and the disease can last a lifetime. MS is most commonly diagnosed in people in their 20s and 30s, but can occur at any age. It is much more common in women than in men.
MS symptoms can manifest themselves differently in everyone. Most common among the symptoms of multiple sclerosis:
- Exhaustion
- Sight problems
- Numbness, tingling
- Balance problems
- Pain and spasms
- Fatigue
Unexplained fatigue and weakness are among the earliest symptoms of MS. About 80 % of patients experience these symptoms. The feeling of weakness usually starts in the legs.
Another most common symptom of MS is vision problems. Problems such as blurred vision, double vision or vision loss may occur.
MS affects the nerves in the brain and spinal cord. Therefore, problems such as tingling and numbness may occur. Numbness and tingling mostly occur in the face, arms, legs and fingers.
Problems such as dizziness and impaired balance can lead to reduced mobility in people with MS.
Chronic pain and muscle spasms are common symptoms in MS patients.
There is no treatment that completely cures MS. However, symptoms can be controlled with certain medications and treatment methods.
There is no special diet for MS patients. However, you can pay attention to your diet to maintain your energy levels and prevent bladder and bowel problems. Low-fat, high-fiber foods are often recommended for people with MS. Foods low in saturated fats and rich in Omega-3 and Omega-6 may be beneficial for MS patients.
Bibliography:
1. "NINDS Multiple Sclerosis Information Page". National Institute of Neurological Disorders and Stroke. 19 November 2015. Retrieved 6 March 2016.
2. Compston A, Coles A (October 2008). "Multiple sclerosis". Lancet 372 (9648): 1502–17.
3. Compston A, Coles A (April 2002). "Multiple sclerosis". Lancet 359 (9313): 1221–31.
4. Murray ED, Buttner EA, Price BH (2012). "Depression and Psychosis in Neurological Practice". In Daroff R, Fenichel G, Jankovic J, Mazziotta J. Bradley’s neurology in clinical practice.(6th ed.). Philadelphia, PA: Elsevier/Saunders.
5. Lublin FD, Reingold SC (April 1996). “Defining the clinical course of multiple sclerosis: results of an international survey”. Neurology 46 (4): 907–11.
6. Kurtzke JF. J Neurovirol 2000;6(suppl 2):S134–S140
7. Munger KL, et al. JAMA 2006;296(23):2832-2838
8. Handel AE, et al. PLoS One 2011;6(1): e16149
9. Ramagopalan SV, et al. Lancet Neurol 2010;9(7):727–739
10. Robertson NP, et al. Brain 1996;119(Pt 2):449–555
11. Ascherio A, Munger KL. Ann Neurol 2007;61(4):288–299
12. Alenda R, et al. Eur J Neurol. 2014;21(8):1096–1101
13. Burton JM, O’Connor PW, Hohol M, Beyene J (12 December 2012). “Oral versus intravenous steroids for treatment of relapses in multiple sclerosis.” The Cochrane database of systematic reviews 12: CD006921.
14. The National Collaborating Centre for Chronic Conditions (2004). Multiple sclerosis : national clinical guideline for diagnosis and management in primary and secondary care(pdf). London: Royal College of Physicians. pp. 54–57.
M-PK-00002248